Aprea Therapeutics, Inc. Form 8-K Summary
Business context and reporting period
Aprea Therapeutics, Inc. filed a Form 8-K relating to corporate governance and Nasdaq listing compliance matters. The reported event occurred on September 16, 2020; the filing was signed September 18, 2020. The company is listed on the Nasdaq Global Select Market under the symbol APRE.
Financial metrics and liquidity
This filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other financial performance metrics. It is not a periodic financial report.
Material changes
- Jonathan Hepple, Ph.D., resigned from the board and its audit committee, effective September 16, 2020.
- Scott Rocklage, Ph.D., also resigned from the board, effective September 16, 2020.
- The company stated that the resignations were not due to disagreements regarding operations, policies, or practices.
- Because of the audit committee vacancy, the company notified Nasdaq that it was no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires a specified audit committee composition.
- The company said it intended to regain compliance within the applicable cure period but did not specify the deadline or a remediation plan in the filing text.
- Christian S. Schade was appointed Chairman of the Board, and John B. Henneman III was appointed Lead Independent Director.
- Richard Peters, M.D., Ph.D., became Chairman of the Compensation Committee, and Fouad Namouni, M.D., joined the Nominating and Corporate Governance Committee.
Outlook, risks, contingencies, and unusual items
The principal disclosed risk is potential continued noncompliance with Nasdaq’s audit committee composition requirements. The filing does not state that delisting proceedings have commenced and does not provide financial guidance or operational outlook. The company furnished a related press release as Exhibit 99.1.
Important facts for investors to verify
- Whether the company reconstituted its audit committee within Nasdaq’s applicable cure period.
- Whether Nasdaq issued any subsequent deficiency, extension, or delisting notice.
- The board and committee composition following the two director resignations.
- Any subsequent filings describing governance changes, financing needs, clinical developments, or liquidity.
- The filing’s date inconsistency: the event date is September 16, while the signature and referenced exhibit are dated September 18, 2020.